Back to first-pass browser

First-pass extracted concept

MAST3

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

MAST3 is presented as a prioritized druggable target candidate for hidradenitis suppurativa from integrated genetic and transcriptomic analyses.

Source 1DOIPubMed

What problem it solves

It provides an additional genetically supported therapeutic target candidate in HS.

Source 1DOIPubMed

What it does not solve

The abstract does not establish a direct therapeutic mechanism or intervention using MAST3 targeting.

Source 1DOIPubMed

Alternatives

The same study also prioritizes PSMA4 and provides stronger cell-type and pathway interpretation for PSMA4.

Source 1DOIPubMed

Evidence Snippets

Colocalization analysis further prioritized PSMA4 and MAST3 as the most promising druggable targets for HS.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1genetic associationsupports2026Source 1DOIPubMed

MAST3 showed a strong statistical association with hidradenitis suppurativa in Mendelian randomization and colocalization analyses.

Quoted textsource-backed
MAST3 (SNPs = 15; IVW OR = 0.557, 95% CI: 0.453-0.686, <i>p</i> < 0.001; PP.H4 = 0.832)
Claim 2target prioritizationsupports2026Source 1DOIPubMed

PSMA4 and MAST3 were prioritized as promising druggable targets for hidradenitis suppurativa by integrated Mendelian randomization and colocalization analyses.

Quoted textsource-backed
Colocalization analysis further prioritized PSMA4 and MAST3 as the most promising druggable targets for HS.
Claim 3transcriptomic observationsupports2026Source 1DOIPubMed

Transcriptomic validation showed that PSMA4 is upregulated and MAST3 is downregulated in hidradenitis suppurativa lesions.

Quoted textsource-backed
Transcriptomic validation revealed that PSMA4 was upregulated and MAST3 was downregulated in HS lesions.